On September 6, the insurance sector witnessed a historic milestone as the Ministry of Finance injected a combined 70 billion yuan into five insurance institutions in a single day. China Life Insurance Group received 35 billion yuan, PICC Group secured up to 15 billion yuan through a private placement, China Taiping obtained 7 billion yuan, Sinosure received 10 billion yuan, and China Reinsurance Group gained 3 billion yuan. This marks the first time in the history of the insurance industry that five leading centrally-administered state-owned insurers have announced capital replenishment plans on the same day.
What makes this even more significant is that this is the inaugural instance of the insurance sector being systematically incorporated into the direct channel of special treasury bond funding. This development signals a redefinition of insurance's strategic position within the national financial security framework. Jiang Han, a senior researcher at Pangoal Institution, noted that the Ministry of Finance's batch capital injection into leading insurance groups signifies a formal transition in China's financial stability assurance system from fragmented, sector-specific risk management to a systemic, pre-emptive reinforcement framework that places insurers on equal footing with major state-owned banks.
Li Wenzhong, deputy director of the Rural Insurance Research Institute at Capital University of Economics and Business, characterized this shift as a paradigm change from "banks alone" to "banks and insurers given equal weight." Li pointed out that while the state previously used special treasury bonds to recapitalize six major state-owned commercial banks, insurance institutions were never systematically included in this framework. Now, with five state-owned insurance groups receiving simultaneous capital injections, the vision of financial stability has extended from the banking system to the insurance system, with a comprehensive state-owned financial capital protection framework covering banks, insurers, and policy-oriented financial institutions now taking initial shape.
The deep logic behind this systemic capital reinforcement spanning life insurance, property insurance, reinsurance, and policy-oriented insurance extends far beyond the figures on paper. It concerns the reconstruction of capital baselines following the full implementation of the "C-ROSS Phase II" rules, the risk-bearing capacity in an era of prolonged interest rate declines and frequent catastrophic events, and the historical mission of state-owned insurers to continue serving as economic shock absorbers and social stabilizers.
Insurance Sector's First Inclusion in Special Bond Capital Injection Framework
The most striking aspect of this capital injection is that its pace has come earlier than market expectations. Tracing the policy trajectory, in May 2025, Li Yunze, then head of the National Financial Regulatory Administration, publicly stated at a State Council Information Office press conference that "capital replenishment for large insurance groups has been put on the agenda." This was the first regulatory signal on the matter. Subsequently, the market held expectations for special bond support for insurer capital injections, but the March 2026 Government Work Report only specified plans to issue 300 billion yuan in special treasury bonds to support capital replenishment for major state-owned commercial banks, with no mention of insurers. At that time, industry consensus was that full coverage of the six major banks would remain the priority in 2026, and insurer capital replenishment might take longer.
That is precisely why the September 6 announcement caught the market by surprise. However, a closer look at the funding arrangement reveals the underlying coordination logic. Within the 300 billion yuan special bond quota, approximately 70 billion yuan was reallocated to insurance institutions. This means that the current capital injections do not represent additional standalone quotas but rather a dynamic optimization within the overall financial injection framework, based on the actual capital needs of different institutions. Regarding the timing, Jiang Han explained that acting when multiple pressures — prolonged interest rate declines and C-ROSS Phase II implementation — approach critical thresholds means building a solid foundation before risks become explicit, confirming for the first time at the national capital level the insurance sector's role as a long-cycle risk buffer.
Li Wenzhong provided a more detailed breakdown from the perspective of triple pressures. He noted that with the implementation of C-ROSS Phase II policies, insurers' solvency ratios have come under pressure to a certain extent, imposing stronger constraints on business development. Prolonged low interest rates are compressing both sides of insurers' balance sheets. Additionally, regulators have been guiding insurers to increase equity allocation ratios and play the role of patient capital, but long-term equity investments consume significant capital. Under these triple pressures, the simultaneous capital injections into state-owned insurers represent, in essence, a forward-looking institutional arrangement. The core logic is to proactively reinforce the safety cushion before pressure fully manifests, rather than waiting for risk exposure before initiating rescue efforts.
In fact, the insurance industry is currently facing the dual pressure of a long-term decline in solvency adequacy ratios and the expiration of the transition period for C-ROSS Phase II rules. Industry-wide data shows that the average comprehensive solvency adequacy ratio for all insurers has been steadily declining from 246.3% at the end of 2020. After the C-ROSS Phase II rules took effect in 2022, the ratio fell to 196% by year-end, and further declined to 181.1% by the end of 2025, with life insurance companies at just 169.3% — nearly 80 percentage points below the 2020 peak. The contraction in core solvency adequacy ratios has been even more pronounced, with the industry average falling from approximately 230% in 2020 to around 130% by the end of 2025.
Zhu Junsheng, a professor and postdoctoral fellow in applied economics at Peking University, stated that the Ministry of Finance's capital injection demonstrates strong forward-thinking. The insurance industry currently faces multiple pressures including prolonged interest rate declines, stricter C-ROSS supervision, and increased capital consumption for equity investments. In the low-interest-rate environment, life insurers are facing rising spread loss risks and accelerated capital consumption. Meanwhile, regulators continue to guide insurance funds to increase equity investment, which requires sufficient capital support. Therefore, this capital injection is less a reactive response to immediate risks and more a proactive reserve of capital strength for development over the next five to ten years. Its purpose is not to resolve short-term operational difficulties but to enhance the capacity of large insurance groups to serve national strategies and undertake long-term investment functions.
Jiang Han also noted that the core function of the 70 billion yuan injection is to create a "capital anchor," stabilizing solvency expectations for leading insurers and preventing localized capital strain from evolving into industry-wide credit contraction. Li Wenzhong shares this view, noting that from a fundamental perspective, the solvency indicators of state-controlled insurance groups are generally well above regulatory red lines, making the Ministry of Finance's injection a pre-emptive preventive measure that further strengthens insurers' solvency and risk resistance. However, he also cautioned that relative to the trillions of yuan in industry assets and liabilities, the 70 billion yuan injection is not large in absolute terms. Its significance lies not in the scale itself but in its signaling effect and the leverage capital exerts on business operations. When leading insurers are no longer constrained by capital limitations, they can accelerate business innovation and development on the liability side, potentially channeling trillion-yuan-scale long-term funds into capital markets and key sectors of the real economy.
Detailed Breakdown of Capital Replenishment Plans for Five Insurers
Turning to the specific plans of the five insurance institutions, while their capital replenishment paths differ, their core objectives are highly unified. China Life received the largest single injection of 35 billion yuan in this round, directly injected by the Ministry of Finance at the group level, involving no changes to the share capital of its listed subsidiary. In its announcement, China Life Group stated that this capital injection is an important national measure to promote high-quality development of the financial and insurance sectors, reflecting both the state's attention to and support for industry development, while also further consolidating the company's operational foundation, enhancing risk resilience, and injecting long-term momentum for the enterprise to focus on its core insurance business, optimize governance structures, and achieve differentiated development.
PICC Group adopted a different approach, issuing A-shares to the Ministry of Finance as a specific target, raising no more than 15 billion yuan, with all proceeds (net of issuance costs) used to supplement capital. PICC noted in its announcement that the insurance industry is currently in a period of deep transformation, with key business tracks such as technology insurance, health insurance, and catastrophe insurance expanding rapidly, and the scale of medium-to-long-term fund allocation and major project investment continuing to grow — all of which place higher demands on the company's capital reserves.
China Taiping received a 7 billion yuan fiscal injection. China Taiping stated it would take this opportunity to focus on its primary business, uphold the political and people-oriented nature of financial work, serve the national strategic landscape with greater commitment and effort, and contribute to accelerating the building of a strong financial nation.
Sinosure received a 10 billion yuan injection, earmarked primarily for strengthening its export credit insurance protection capacity to support stable foreign trade development. China Reinsurance Group will have the Ministry of Finance subscribe for 3 billion yuan worth of domestic shares in cash at 1.33 yuan per share — a premium to its recent H-share secondary market price — with the subscriber committing to long-term holding. China Re specifically noted that supporting central financial enterprises in supplementing core Tier-1 capital is an important component of the national package of incremental policies. The company stated it would use this issuance as an opportunity to solidly implement the "five key articles" in finance, comprehensively enhance its capacity to address complex and emerging risks, continuously expand global competitiveness and international market influence, and play a greater role in fulfilling its responsibilities as the mainstay of reinsurance.
The 70 billion yuan capital injection has now been finalized, covering core sectors including life insurance, property insurance, reinsurance, and policy-oriented insurance — a truly systemic industry capital reinforcement. All companies are remarkably consistent in their messaging: the funds will be used entirely to supplement capital or core Tier-1 capital, all aimed at strengthening capital foundations and enhancing prudent operations and risk resilience. Regarding the choice of injection methods, Jiang Han analyzed that the dual-path approach of direct injection and private placement is fundamentally about abandoning a one-size-fits-all model and selecting the most efficient capital supplement method based on institutional characteristics. Non-listed groups like China Life and China Taiping take the direct injection path, quickly solidifying core Tier-1 capital. Listed insurers like PICC and China Re raise capital through private placements, supplementing capital in compliance while maintaining the transparency and stability of existing market-oriented governance structures.
Zhu Junsheng also noted that while the two methods differ in form, they are essentially both supplementing core Tier-1 capital, with the differences reflecting variations in each group's existing ownership structure, capital operation mechanisms, and governance arrangements. Li Wenzhong provided a clearer explanation from a procedural perspective. He pointed out that PICC and China Re are both wholly-listed groups, so capital increases must follow the procedures for listed company private placements. The other three companies are non-listed at their own level, allowing for direct injection. Of course, direct injection also requires equity valuation and pricing to ensure fairness and safeguard state-owned asset security, though the procedures are relatively simpler. The common goals are to enhance capital strength, improve capacity to serve national strategies, and strengthen risk resilience.
The capital injection amounts vary significantly across the five institutions, ranging from 3 billion to 35 billion yuan. This is not a simple matter of scale matching but a strategically calculated allocation. Jiang Han told reporters that the disparate allocation from 3 billion to 35 billion is by no means an equal distribution, but rather a precise match based on three dimensions: strategic weight, capital gap, and public function. Institutions like China Life, which bear the heaviest long-term protection functions among life insurance state-owned enterprises, receive the highest allocation, while institutions with faster capital consumption and policy-oriented insurers serving foreign trade and national strategies also receive corresponding injection scales.
Li Wenzhong provided a detailed breakdown based on each institution's specific functions. He noted that China Life Group received the highest amount of 35 billion yuan because it is China's largest insurance group with massive assets under management, bearing important responsibilities in national strategic areas such as pension finance and health insurance. Moreover, since its asset-liability business is predominantly long-term in nature, capital consumption has accelerated noticeably after C-ROSS Phase II implementation, and capital replenishment can directly boost solvency to better support its service to national pension and health strategies. PICC received 15 billion yuan; as a listed insurance group primarily focused on property insurance, it plays an important role in policy-oriented businesses such as catastrophe insurance and agricultural insurance, and capital supplementation helps it better fulfill its function as an economic shock absorber and social stabilizer.
"Sinosure received 10 billion yuan; as a policy-oriented export credit insurance institution, its function is to support export trade and overseas investment, better serving the Belt and Road Initiative. China Taiping received 7 billion yuan; as a state-owned insurance group headquartered overseas, it holds a unique position in cross-border insurance services and internationalization. China Re received 3 billion yuan; as a reinsurance group, its capital needs are relatively smaller, but supplementing core Tier-1 capital helps solidify its capital foundation and comprehensively enhance development across key business lines." Li Wenzhong noted that overall, this allocation plan reflects the principle that "functional positioning determines injection scale," matching the strategic roles and capital consumption structures of each institution. Zhu Junsheng also concurred with this assessment, believing that the injection scale actually reflects the state's arrangement of future functional positioning for different institutions.
From Solvency Support to Patient Capital Release
Jiang Han emphasized that with capital replenished, the "capital shackles" on insurers' equity investments will be directly unlocked, changing the previous situation where high capital consumption constraints prevented increased equity allocation. The 70 billion yuan injection will not flow directly into the market in its entirety, but by enhancing the risk tolerance of leading insurers, it can leverage several times that amount in long-term patient capital entering capital markets and real-economy equity projects.
Li Wenzhong provided more specific calculation logic from the perspective of solvency regulatory rules: under solvency regulations, equity investment is the area of highest capital consumption. When insurers allocate to equity assets, they must set aside substantial solvency capital. When capital adequacy ratios are under pressure, insurers are often forced to reduce equity allocation ratios. With solvency supplemented, the capital shackles restricting increased equity allocation can be further unlocked, allowing insurers to better respond to the call for long-term funds to enter the market and fulfill the patient capital role of insurance funds. This could potentially leverage trillion-yuan-scale funds into the capital market.
Zhu Junsheng also pointed out that equity assets such as stocks consume relatively high capital. When capital strength is insufficient, even if insurers have allocation demand, they cannot significantly increase equity investment ratios. Under insurance capital regulatory logic, this capital replenishment of 70 billion yuan is expected to unlock long-term fund allocation capacity of several hundred billion yuan. Looking at a longer cycle, large insurance groups can not only increase equity investment ratios but also strengthen long-term investment in areas such as technological innovation, advanced manufacturing, green development, and infrastructure construction.
Furthermore, this capital injection also serves to build a "buffer zone" for risk transmission. In past years, whenever risk events emerged in the insurance industry, it was the leading state-owned insurers that bore the brunt of risk containment and transmission prevention. During the 2023 resolution of Huaxia Life's risks, it was 11 leading life insurers including China Life Life and Taiping Life that jointly with local governments and the Insurance Security Fund invested 33.9 billion yuan to establish a special fund to assume related assets and liabilities. Subsequent risk resolutions involving Hengda Life and other institutions also saw deep participation from leading insurers. This "industry firefighting" role determines that leading insurers must maintain capital reserves far exceeding industry averages.
Regarding the impact on industry dynamics, Jiang Han believes that capital reinforcement for leading state-owned insurers will not simply crowd out smaller insurers from the market. Instead, it will first elevate the industry's overall credit foundation and build a bottom-layer safety net. It will not trigger "big fish eat small fish" involution but rather drive industry stratification: leaders focus on long-term protection and strategic services, while smaller insurers can escape homogeneous competition under capital anxiety and pivot toward differentiated survival paths in regional markets and niche segments.
Li Wenzhong holds a slightly different perspective. He noted that the Matthew effect (cumulative advantage) is pronounced in China's current insurance market, and fiscal capital injections for state-owned large insurance groups will further enhance these companies' market competitiveness, which is clearly disadvantageous to smaller companies that will face greater pressure. However, the strengthening of leading insurers' capital strength also has positive implications for the entire industry. As the industry's "ballast stone" and "stabilizer," the sound operation of leading insurers itself maintains confidence in the overall industry and effectively prevents systemic risks from impacting the sector, which to a certain extent shares risk pressure with smaller insurers.
Zhu Junsheng also noted that the state is building large insurance groups with global competitiveness and systemic stability functions. The objective result is likely to be further strengthening of leading state-owned insurance groups, increased industry concentration, and greater transformation pressure on smaller insurers. But from an overall industry perspective, large insurance groups with strong capital strength are not merely market competitors; they will increasingly assume the roles of industry stabilizers and risk buffers, potentially playing more significant roles in future industry risk resolution and market stability.